{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T05:45:43Z","timestamp":1791265543551,"version":"4.1.0"},"reference-count":75,"publisher":"Elsevier BV","issue":"47","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,15]],"date-time":"2021-10-15T00:00:00Z","timestamp":1634256000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI106878"],"award-info":[{"award-number":["AI106878"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI137164"],"award-info":[{"award-number":["AI137164"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["221595\/Z\/20\/Z"],"award-info":[{"award-number":["221595\/Z\/20\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000061","name":"Fogarty International Center","doi-asserted-by":"publisher","award":["TW010362"],"award-info":[{"award-number":["TW010362"]}],"id":[{"id":"10.13039\/100000061","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000061","name":"Fogarty International Center","doi-asserted-by":"publisher","award":["TW005572"],"award-info":[{"award-number":["TW005572"]}],"id":[{"id":"10.13039\/100000061","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.vaccine.2021.10.005","type":"journal-article","created":{"date-parts":[[2021,10,27]],"date-time":"2021-10-27T04:28:54Z","timestamp":1635308934000},"page":"6936-6946","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Scalable production and immunogenicity of a cholera conjugate vaccine"],"prefix":"10.1016","volume":"39","author":[{"given":"Suhi","family":"Jeon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meagan","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeesun","family":"Yun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byungman","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minchul","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoonhee","family":"Whang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chankyu","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan-Di","family":"Halvorsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3760-8090","authenticated-orcid":false,"given":"Smriti","family":"Verma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8881-1849","authenticated-orcid":false,"given":"Richelle C.","family":"Charles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason B.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2083-7153","authenticated-orcid":false,"given":"Stephen B.","family":"Calderwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8401-0801","authenticated-orcid":false,"given":"Daniel T.","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taufiqur R.","family":"Bhuiyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Firdausi","family":"Qadri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7954-673X","authenticated-orcid":false,"given":"Mohammad","family":"Kamruzzaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3859-2745","authenticated-orcid":false,"given":"Somyoung","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willie F.","family":"Vann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1867-0059","authenticated-orcid":false,"given":"Peng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5044-3449","authenticated-orcid":false,"given":"Pavol","family":"Kov\u00e1\u010d","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5945-3969","authenticated-orcid":false,"given":"Ravi","family":"Ganapathy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Lynch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward T.","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2021.10.005_b0005","doi-asserted-by":"crossref","unstructured":"Harris JB, LaRocque RC, Qadri F, Ryan ET, Calderwood SB. Cholera. Lancet. 2012;379(9835):2466-76. PMC3761070.","DOI":"10.1016\/S0140-6736(12)60436-X"},{"key":"10.1016\/j.vaccine.2021.10.005_b0010","doi-asserted-by":"crossref","unstructured":"Ali M, Nelson AR, Lopez AL, Sack DA. Updated global burden of cholera in endemic countries. PLoS Negl Trop Dis. 2015;9(6):e0003832. PMC4455997.","DOI":"10.1371\/journal.pntd.0003832"},{"key":"10.1016\/j.vaccine.2021.10.005_b0015","doi-asserted-by":"crossref","unstructured":"Pezzoli L, Oral Cholera Vaccine Working Group of the Global Task Force on Cholera C. Global oral cholera vaccine use, 2013-2018. Vaccine. 2020;38 Suppl 1:A132-A40. PMID: 31519444.","DOI":"10.1016\/j.vaccine.2019.08.086"},{"key":"10.1016\/j.vaccine.2021.10.005_b0020","doi-asserted-by":"crossref","unstructured":"Legros D, Partners of the Global Task Force on Cholera Control. Global Cholera Epidemiology: opportunities to reduce the burden of cholera by 2030. J Infect Dis. 2018;218(suppl_3):S137-S40. PMC6207143.","DOI":"10.1093\/infdis\/jiy486"},{"key":"10.1016\/j.vaccine.2021.10.005_b0025","doi-asserted-by":"crossref","unstructured":"Sur D, Kanungo S, Sah B, Manna B, Ali M, Paisley AM, et al. Efficacy of a low-cost, inactivated whole-cell oral cholera vaccine: results from 3 years of follow-up of a randomized, controlled trial. PLoS Negl Trop Dis. 2011;5(10):e1289. PMC3196468.","DOI":"10.1371\/journal.pntd.0001289"},{"key":"10.1016\/j.vaccine.2021.10.005_b0030","doi-asserted-by":"crossref","unstructured":"Sinclair D, Abba K, Zaman K, Qadri F, Graves PM. Oral vaccines for preventing cholera. Cochrane Database Syst Rev. 2011;(3):CD008603. PMC6532691.","DOI":"10.1002\/14651858.CD008603.pub2"},{"issue":"5","key":"10.1016\/j.vaccine.2021.10.005_b0035","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1128\/CVI.05615-11","article-title":"Memory B cell and other immune responses in children receiving two doses of an oral killed cholera vaccine compared to responses following natural cholera infection in Bangladesh","volume":"19","author":"Leung","year":"2012","journal-title":"Clin Vaccine Immunol"},{"issue":"49","key":"10.1016\/j.vaccine.2021.10.005_b0040","doi-asserted-by":"crossref","first-page":"6887","DOI":"10.1016\/j.vaccine.2009.09.008","article-title":"Immune responses following one and two doses of the reformulated, bivalent, killed, whole-cell, oral cholera vaccine among adults and children in Kolkata, India: a randomized, placebo-controlled trial","volume":"27","author":"Kanungo","year":"2009","journal-title":"Vaccine."},{"issue":"46","key":"10.1016\/j.vaccine.2021.10.005_b0045","doi-asserted-by":"crossref","first-page":"8285","DOI":"10.1016\/j.vaccine.2011.08.108","article-title":"Safety and immunogenicity study of a killed bivalent (O1 and O139) whole-cell oral cholera vaccine Shanchol, in Bangladeshi adults and children as young as 1 year of age","volume":"29","author":"Saha","year":"2011","journal-title":"Vaccine."},{"issue":"3","key":"10.1016\/j.vaccine.2021.10.005_b0050","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.trstmh.2007.10.015","article-title":"Use of Lot Quality Assurance Sampling (LQAS) to estimate vaccination coverage helps guide future vaccination efforts","volume":"102","author":"Alberti","year":"2008","journal-title":"Trans R Soc Trop Med Hyg."},{"issue":"3","key":"10.1016\/j.vaccine.2021.10.005_b0055","doi-asserted-by":"crossref","first-page":"209","DOI":"10.2471\/BLT.11.093427","article-title":"The global burden of cholera","volume":"90","author":"Ali","year":"2012","journal-title":"Bull World Health Organ."},{"key":"10.1016\/j.vaccine.2021.10.005_b0060","unstructured":"Gavi-the Vaccine Alliance; Cholera Supply and Procurement Roadmap UPDATE 14th December 2018; p4 https:\/\/www.gavi.org\/our-alliance\/market-shaping\/supply-and-procurement-roadmaps2018 [June 3, 2021]."},{"key":"10.1016\/j.vaccine.2021.10.005_b0065","unstructured":"Global Task Force on Cholera Control GTFCC: Cholera Vaccines Research Priorities; OCV Working Group 2019; p3 https:\/\/www.gtfcc.org\/wp-content\/uploads\/2020\/08\/6th-gtfcc-working-group-on-ocv-meeting-2019-research-priorities.pdf2019 [June 3, 2021]."},{"key":"10.1016\/j.vaccine.2021.10.005_b0070","unstructured":"Global Task Force on Cholera Control GTFCC: Cholera Roadmap Research Agenda; 2021Vaccines Research Priorities; p16 https:\/\/www.gtfcc.org\/wp-content\/uploads\/2021\/01\/gtfcc-global-roadmap-research-agenda-full-report-with-methodology.pdf2021 [June 3, 2021]."},{"key":"10.1016\/j.vaccine.2021.10.005_b0075","doi-asserted-by":"crossref","unstructured":"Islam K, Hossain M, Kelly M, Mayo Smith LM, Charles RC, Bhuiyan TR, et al. Anti-O-specific polysaccharide (OSP) immune responses following vaccination with oral cholera vaccine CVD 103-HgR correlate with protection against cholera after infection with wild-type Vibrio cholerae O1 El Tor Inaba in North American volunteers. PLoS Negl Trop Dis. 2018;12(4):e0006376. PMC5906022.","DOI":"10.1371\/journal.pntd.0006376"},{"issue":"4","key":"10.1016\/j.vaccine.2021.10.005_b0080","doi-asserted-by":"crossref","first-page":"MC5912711","DOI":"10.1371\/journal.pntd.0006399","article-title":"Plasma and memory B cell responses targeting O-specific polysaccharide (OSP) are associated with protection against Vibrio cholerae O1 infection among household contacts of cholera patients in Bangladesh","volume":"12","author":"Aktar","year":"2018","journal-title":"PLoS Negl Trop Dis"},{"issue":"19","key":"10.1016\/j.vaccine.2021.10.005_b0085","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1001\/jama.280.19.1685","article-title":"Induction of immunologic memory by conjugated vs plain meningococcal C polysaccharide vaccine in toddlers: a randomized controlled trial","volume":"280","author":"MacDonald","year":"1998","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.vaccine.2021.10.005_b0090","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/nri2494","article-title":"Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines","volume":"9","author":"Pollard","year":"2009","journal-title":"Nat Rev Immunol."},{"key":"10.1016\/j.vaccine.2021.10.005_b0095","doi-asserted-by":"crossref","unstructured":"Clutterbuck EA, Lazarus R, Yu LM, Bowman J, Bateman EA, Diggle L, et al. Pneumococcal conjugate and plain polysaccharide vaccines have divergent effects on antigen-specific B cells. J Infect Dis. 2012;205(9):1408-16. PMC3324398.","DOI":"10.1093\/infdis\/jis212"},{"issue":"5","key":"10.1016\/j.vaccine.2021.10.005_b0100","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1128\/CVI.00791-13","article-title":"Immune responses to Vi capsular polysaccharide typhoid vaccine in children 2 to 16 years old in Karachi, Pakistan, and Kolkata, India","volume":"21","author":"Ochiai","year":"2014","journal-title":"Clin Vaccine Immunol"},{"issue":"5","key":"10.1016\/j.vaccine.2021.10.005_b0105","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1128\/CVI.00532-10","article-title":"The Vi conjugate typhoid vaccine is safe, elicits protective levels of IgG anti-Vi, and is compatible with routine infant vaccines","volume":"18","author":"Thiem","year":"2011","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2021.10.005_b0110","doi-asserted-by":"crossref","unstructured":"Truck J, Mitchell R, Jawad S, Clutterbuck EA, Snape MD, Kelly DF, et al. Divergent memory B cell responses in a mixed infantpneumococcal conjugate vaccine schedule. Pediatr Infect Dis J. 2017;36(5):e130\u2013e5. PMID: 28027283.","DOI":"10.1097\/INF.0000000000001497"},{"key":"10.1016\/j.vaccine.2021.10.005_b0115","unstructured":"Benenson AS, Mosley WH, Fahimuddin M, Oseasohn RO. Cholera vaccine field trials in east Pakistan. 2. Effectiveness in the field. Bull World Health Organ. 1968;38(3):359\u201372. PMC2554494."},{"key":"10.1016\/j.vaccine.2021.10.005_b0120","unstructured":"Benenson AS, Joseph PR, Oseasohn RO. Cholera vaccine field trials in east Pakistan. 1. Reaction and antigenicity studies. Bull World Health Organ. 1968;38(3):347\u201357. PMC2554479."},{"key":"10.1016\/j.vaccine.2021.10.005_b0125","unstructured":"Das Gupta A, Sinha R, Shrivastava DL, De SP, Taneja BL, Rao MS, et al. Controlled field trial of the effectiveness of cholera and cholera El Tor vaccines in Calcutta. Bull World Health Organ. 1967;37(3):371\u201385. PMC2554277."},{"key":"10.1016\/j.vaccine.2021.10.005_b0130","unstructured":"Azurin JC, Cruz A, Pesigan TP, Alvero M, Camena T, Suplido R, et al. A controlled field trial of the effectiveness of cholera and cholera El Tor vaccines in the Philippines. Bull World Health Organ. 1967;37(5):703-27. PMC2554919."},{"key":"10.1016\/j.vaccine.2021.10.005_b0135","unstructured":"Mosley WH, Benenson AS, Barui R. A serological survey for cholera antibodies in rural east Pakistan. 2. A comparison of antibody titres in the innunized and control populationd of a cholera-vaccine field-trial area and the relation of antibody titre to cholera case rate. Bull World Health Organ. 1968;38(3):335\u201346. PMC2554488."},{"key":"10.1016\/j.vaccine.2021.10.005_b0140","unstructured":"A controlled field trial of the effectiveness of various doses of cholera El Tor vaccine in the Philippines. Bull World Health Organ. 1968;38(6):917-23. PMC2554519."},{"key":"10.1016\/j.vaccine.2021.10.005_b0145","unstructured":"Mosley WH, McCormack WM, Fahimuddin M, Aziz KM, Rahman AS, Chowdhury AK, et al. Report of the 1966-67 cholera vaccine field trial in rural East Pakistan. I. Study design and results of the first year of observation. Bull World Health Organ. 1969;40(2):177\u201385. PMC2554610."},{"key":"10.1016\/j.vaccine.2021.10.005_b0150","doi-asserted-by":"crossref","unstructured":"Sayeed MA, Bufano MK, Xu P, Eckhoff G, Charles RC, Alam MM, et al. A Cholera Conjugate vaccine containing O-specific polysaccharide (OSP) of V. cholerae O1 Inaba and recombinant fragment of tetanus toxin heavy chain (OSP:rTTHc) induces serum, memory and lamina proprial responses against OSP and is protective in mice. PLoS Negl Trop Dis. 2015;9(7):e0003881. PMC4495926.","DOI":"10.1371\/journal.pntd.0003881"},{"key":"10.1016\/j.vaccine.2021.10.005_b0155","doi-asserted-by":"crossref","unstructured":"Alam MM, Bufano MK, Xu P, Kalsy A, Yu Y, Freeman YW, et al. Evaluation in mice of a conjugate vaccine for cholera made from Vibrio cholerae O1 (Ogawa) O-specific polysaccharide. PLoS Negl Trop Dis. 2014;8(2):e2683. PMC3916310.","DOI":"10.1371\/journal.pntd.0002683"},{"issue":"4","key":"10.1016\/j.vaccine.2021.10.005_b0160","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1128\/CVI.05689-11","article-title":"Transcutaneous immunization with a Vibrio cholerae O1 Ogawa synthetic hexasaccharide conjugate following oral whole-cell cholera vaccination boosts vibriocidal responses and induces protective immunity in mice","volume":"19","author":"Tarique","year":"2012","journal-title":"Clin Vaccine Immunol"},{"issue":"36","key":"10.1016\/j.vaccine.2021.10.005_b0165","doi-asserted-by":"crossref","first-page":"4917","DOI":"10.1016\/j.vaccine.2009.06.040","article-title":"Transcutaneous immunization with a synthetic hexasaccharide-protein conjugate induces anti-Vibrio cholerae lipopolysaccharide responses in mice","volume":"27","author":"Rollenhagen","year":"2009","journal-title":"Vaccine."},{"issue":"1","key":"10.1016\/j.vaccine.2021.10.005_b0170","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0022-1759(96)00146-9","article-title":"Limiting dilution analysis of virus-specific memory B cells by an ELISPOT assay","volume":"199","author":"Slifka","year":"1996","journal-title":"J Immunol Methods"},{"issue":"10","key":"10.1016\/j.vaccine.2021.10.005_b0175","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/S1473-3099(17)30359-6","article-title":"Protection against cholera from killed whole-cell oral cholera vaccines: a systematic review and meta-analysis","volume":"17","author":"Bi","year":"2017","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2021.10.005_b0180","doi-asserted-by":"crossref","first-page":"e221","DOI":"10.1371\/journal.pntd.0000221","article-title":"Susceptibility to Vibrio cholerae infection in a cohort of household contacts of patients with cholera in Bangladesh","volume":"2","author":"Harris","year":"2008","journal-title":"PLoS Negl Trop Dis."},{"issue":"4","key":"10.1016\/j.vaccine.2021.10.005_b0185","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1093\/infdis\/145.4.465","article-title":"Magnitude, kinetics, and duration of vibriocidal antibody responses in North Americans after ingestion of Vibrio cholerae","volume":"145","author":"Clements","year":"1982","journal-title":"J Infect Dis"},{"issue":"11","key":"10.1016\/j.vaccine.2021.10.005_b0190","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1128\/CVI.00321-12","article-title":"Comparison of immune responses to the O-specific polysaccharide and lipopolysaccharide of Vibrio cholerae O1 in Bangladeshi adult patients with cholera","volume":"19","author":"Johnson","year":"2012","journal-title":"Clin Vaccine Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2021.10.005_b0195","doi-asserted-by":"crossref","DOI":"10.1128\/IAI.00626-16","article-title":"Immunity provided by an outer membrane vesicle cholera vaccine Is due to O-antigen-specific antibodies inhibiting bacterial motility","volume":"85","author":"Wang","year":"2017","journal-title":"Infect Immun"},{"issue":"10","key":"10.1016\/j.vaccine.2021.10.005_b0200","doi-asserted-by":"crossref","first-page":"4402","DOI":"10.1128\/IAI.00398-10","article-title":"Mucosal immunization with Vibrio cholerae outer membrane vesicles provides maternal protection mediated by antilipopolysaccharide antibodies that inhibit bacterial motility","volume":"78","author":"Bishop","year":"2010","journal-title":"Infect Immun"},{"issue":"6","key":"10.1016\/j.vaccine.2021.10.005_b0205","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.02847-20","article-title":"Humans surviving cholera develop antibodies against Vibrio cholerae O-specific polysaccharide that inhibit pathogen motility","volume":"11","author":"Charles","year":"2020","journal-title":"mBio."},{"issue":"2","key":"10.1016\/j.vaccine.2021.10.005_b0210","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.03679-20","article-title":"Impact of immunoglobulin isotype and epitope on the functional properties of Vibrio cholerae O-specific polysaccharide-specific monoclonal antibodies","volume":"12","author":"Kauffman","year":"2021","journal-title":"mBio."},{"issue":"1","key":"10.1016\/j.vaccine.2021.10.005_b0215","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1093\/infdis\/169.1.230","article-title":"Lack of cross-protection against diarrhea due to Vibrio cholerae O139 (Bengal strain) after oral immunization of rabbits with V. cholerae O1 vaccine strain CVD103-HgR","volume":"169","author":"Albert","year":"1994","journal-title":"J Infect Dis"},{"issue":"9","key":"10.1016\/j.vaccine.2021.10.005_b0220","doi-asserted-by":"crossref","first-page":"3571","DOI":"10.1128\/iai.65.9.3571-3576.1997","article-title":"Comparison of immune responses in patients infected with Vibrio cholerae O139 and O1","volume":"65","author":"Qadri","year":"1997","journal-title":"Infect Immun"},{"issue":"24","key":"10.1016\/j.vaccine.2021.10.005_b0225","doi-asserted-by":"crossref","first-page":"11388","DOI":"10.1073\/pnas.91.24.11388","article-title":"The Vibrio cholerae O139 serogroup antigen includes an O-antigen capsule and lipopolysaccharide virulence determinants","volume":"91","author":"Waldor","year":"1994","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"1","key":"10.1016\/j.vaccine.2021.10.005_b0230","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1006\/bbrc.1993.1046","article-title":"Occurrence of 2-O-methyl-N-(3-deoxy-L-glycero-tetronyl)-D-perosamine (4-amino-4,6-dideoxy-D-manno-pyranose) in lipopolysaccharide from Ogawa but not from Inaba O forms of O1 Vibrio cholerae","volume":"190","author":"Hisatsune","year":"1993","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.vaccine.2021.10.005_b0235","unstructured":"Gilmour CB. Period of excretion of Vibrio cholerae in convalescents. Bull World Health Organ. 1952;7(3):343\u201351. PMC2554157."},{"key":"10.1016\/j.vaccine.2021.10.005_b0240","doi-asserted-by":"crossref","unstructured":"Mosley WH, Woodward WE, Aziz KM, Rahman AS, Chowdhury AK, Ahmed A, et al. The 1968-1969 cholera-vaccine field trial in rural East Pakistan. Effectiveness of monovalent Ogawa and Inaba vaccines and a purified Inaba antigen, with comparative results of serological and animal protection tests. J Infect Dis. 1970;121:Suppl 121:1-9. PMID: 4912069.","DOI":"10.1093\/infdis\/121.Supplement.S1"},{"issue":"7491","key":"10.1016\/j.vaccine.2021.10.005_b0245","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/S0140-6736(67)92542-1","article-title":"Multiple serotypes of Vibrio cholerae isolated from a case of cholera Evidence suggesting in-vivo mutation","volume":"1","author":"Gangarosa","year":"1967","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.vaccine.2021.10.005_b0250","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s10719-009-9259-4","article-title":"Multimeric bivalent immunogens from recombinant tetanus toxin HC fragment, synthetic hexasaccharides, and a glycopeptide adjuvant","volume":"27","author":"Bongat","year":"2010","journal-title":"Glycoconj J"},{"issue":"1","key":"10.1016\/j.vaccine.2021.10.005_b0255","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-59711-y","article-title":"Preclinical development of a fusion peptide conjugate as an HIV vaccine immunogen","volume":"10","author":"Ou","year":"2020","journal-title":"Sci Rep"},{"issue":"12","key":"10.1016\/j.vaccine.2021.10.005_b0260","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1097\/INF.0000000000001601","article-title":"Pneumococcal immune response in infants whose mothers received tetanus, diphtheria and acellular pertussis vaccination during pregnancy","volume":"36","author":"Maertens","year":"2017","journal-title":"Pediatr Infect Dis J"},{"issue":"11","key":"10.1016\/j.vaccine.2021.10.005_b0265","doi-asserted-by":"crossref","first-page":"5806","DOI":"10.1128\/IAI.67.11.5806-5810.1999","article-title":"Safety and immunogenicity of Vi conjugate vaccines for typhoid fever in adults, teenagers, and 2- to 4-year-old children in Vietnam","volume":"67","author":"Burns","year":"1999","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2021.10.005_b0270","doi-asserted-by":"crossref","unstructured":"Cross DL, Verheul MK, Leipold MD, Obermoser G, Jin C, Jones E, et al. Vi-Vaccinations induce heterogeneous plasma cell responses that associate with protection from typhoid fever. Front Immunol. 2020;11:574057. PMC7793947.","DOI":"10.3389\/fimmu.2020.574057"},{"key":"10.1016\/j.vaccine.2021.10.005_b0275","unstructured":"Ganguly R, Clem LW, Bencic Z, Sinha R, Sakazaki R, Waldman RH. Antibody response in the intestinal secretions of volunteers immunized with various cholera vaccines. Bull World Health Organ. 1975;52(3):323\u201330. PMC2366383."},{"issue":"12","key":"10.1016\/j.vaccine.2021.10.005_b0280","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1111\/j.1365-3083.1977.tb00376.x","article-title":"Boosting of secretory IgA antibody responses in man by parenteral cholera vaccination","volume":"6","author":"Svennerholm","year":"1977","journal-title":"Scand J Immunol"},{"issue":"4","key":"10.1016\/j.vaccine.2021.10.005_b0285","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/j.1365-3083.1988.tb01474.x","article-title":"Polymeric and monomeric IgA response in serum and milk after parenteral cholera and oral typhoid vaccination","volume":"28","author":"Mascart-Lemone","year":"1988","journal-title":"Scand J Immunol"},{"issue":"4","key":"10.1016\/j.vaccine.2021.10.005_b0290","doi-asserted-by":"crossref","first-page":"421","DOI":"10.3109\/00365548909167447","article-title":"The influence on the secretory IgA antibody levels in lactating women of oral typhoid and parenteral cholera vaccines given alone or in combination","volume":"21","author":"Hahn-Zoric","year":"1989","journal-title":"Scand J Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2021.10.005_b0295","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S1473-3099(01)00063-9","article-title":"Efficacy of pneumococcal conjugate vaccines and their effect on carriage and antimicrobial resistance","volume":"1","author":"Klugman","year":"2001","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2021.10.005_b0300","doi-asserted-by":"crossref","unstructured":"Daugla DM, Gami JP, Gamougam K, Naibei N, Mbainadji L, Narbe M, et al. Effect of a serogroup A meningococcal conjugate vaccine (PsA-TT) on serogroup A meningococcal meningitis and carriage in Chad: a community study [corrected]. Lancet. 2014;383(9911):40-7. PMC3898950.","DOI":"10.1016\/S0140-6736(13)61612-8"},{"issue":"5","key":"10.1016\/j.vaccine.2021.10.005_b0305","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1093\/infdis\/164.5.982","article-title":"Reduction of oropharyngeal carriage of Haemophilus influenzae type b (Hib) in children immunized with an Hib conjugate vaccine","volume":"164","author":"Takala","year":"1991","journal-title":"J Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2021.10.005_b0310","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1097\/00006454-199306000-00005","article-title":"Haemophilus influenzae type b carriage and immunity four years after receiving the Haemophilus influenzae oligosaccharide-CRM197 (HbOC) conjugate vaccine","volume":"12","author":"Barbour","year":"1993","journal-title":"Pediatr Infect Dis J"},{"issue":"7","key":"10.1016\/j.vaccine.2021.10.005_b0315","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1097\/00006454-199307000-00010","article-title":"Vaccination with Haemophilus influenzae type b meningococcal protein conjugate vaccine reduces oropharyngeal carriage of Haemophilus influenzae type b among American Indian children","volume":"12","author":"Takala","year":"1993","journal-title":"Pediatr Infect Dis J"},{"issue":"4","key":"10.1016\/j.vaccine.2021.10.005_b0320","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0022-3476(05)83529-2","article-title":"Decreased Haemophilus colonization in children vaccinated with Haemophilus influenzae type b conjugate vaccine","volume":"122","author":"Murphy","year":"1993","journal-title":"J Pediatr"},{"key":"10.1016\/j.vaccine.2021.10.005_b0325","doi-asserted-by":"crossref","unstructured":"Safadi MA, Carvalhanas TR, Paula de Lemos A, Gorla MC, Salgado M, Fukasawa LO, et al. Carriage rate and effects of vaccination after outbreaks of serogroup C meningococcal disease, Brazil, 2010. Emerg Infect Dis. 2014;20(5):806-11. PMC4012795.","DOI":"10.3201\/eid2005.130948"},{"issue":"11","key":"10.1016\/j.vaccine.2021.10.005_b0330","doi-asserted-by":"crossref","first-page":"PMC7693901","DOI":"10.3390\/microorganisms8111675","article-title":"Herd Protection against meningococcal disease through vaccination","volume":"8","author":"Clark","year":"2020","journal-title":"Microorganisms."},{"issue":"5","key":"10.1016\/j.vaccine.2021.10.005_b0335","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1128\/IAI.68.5.2692-2697.2000","article-title":"Mucosal immune responses to meningococcal group C conjugate and group A and C polysaccharide vaccines in adolescents","volume":"68","author":"Clements","year":"2000","journal-title":"Infect Immun"},{"issue":"7","key":"10.1016\/j.vaccine.2021.10.005_b0340","doi-asserted-by":"crossref","first-page":"4337","DOI":"10.1128\/IAI.69.7.4337-4341.2001","article-title":"Primary and booster mucosal immune responses to meningococcal group A and C conjugate and polysaccharide vaccines administered to university students in the United Kingdom","volume":"69","author":"Clements","year":"2001","journal-title":"Infect Immun"},{"issue":"2","key":"10.1016\/j.vaccine.2021.10.005_b0345","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1017\/S0950268899002915","article-title":"Salivary antibodies following parenteral immunization of infants with a meningococcal serogroup A and C conjugated vaccine","volume":"123","author":"Borrow","year":"1999","journal-title":"Epidemiol Infect"},{"issue":"4\u20135","key":"10.1016\/j.vaccine.2021.10.005_b0350","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0264-410X(00)00180-8","article-title":"Salivary antibody response to vaccination with meningococcal A\/C polysaccharide vaccine in previously vaccinated and unvaccinated Gambian children","volume":"19","author":"Nurkka","year":"2000","journal-title":"Vaccine."},{"issue":"2","key":"10.1016\/j.vaccine.2021.10.005_b0355","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/sji.12451","article-title":"Salivary and serum antibody response against Neisseria meningitidis after vaccination with conjugate polysaccharide vaccines in Ethiopian volunteers","volume":"84","author":"B\u00e5rnes","year":"2016","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.vaccine.2021.10.005_b0360","doi-asserted-by":"crossref","unstructured":"van Ravenhorst MB, den Hartog G, van der Klis FRM, van Rooijen DM, Sanders EAM, Berbers GAM. Induction of salivary antibody levels in Dutch adolescents after immunization with monovalent meningococcal serogroup C or quadrivalent meningococcal serogroup A, C, W and Y conjugate vaccine. PLoS One. 2018;13(4):e0191261. PMC5908077.","DOI":"10.1371\/journal.pone.0191261"},{"issue":"1","key":"10.1016\/j.vaccine.2021.10.005_b0365","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1128\/iai.2.1.29-37.1970","article-title":"Antibody responses in serum, secretions, and urine of man after parenteral administration of vaccines","volume":"2","author":"Sirisinha","year":"1970","journal-title":"Infect Immun"},{"issue":"10","key":"10.1016\/j.vaccine.2021.10.005_b0370","doi-asserted-by":"crossref","DOI":"10.1128\/CVI.00188-17","article-title":"Effect of vaccine-elicited antibodies on colonization of Neisseria meningitidis Serogroup B and C strains in a human bronchial epithelial cell culture model","volume":"24","author":"Vianzon","year":"2017","journal-title":"Clin Vaccine Immunol"},{"issue":"10","key":"10.1016\/j.vaccine.2021.10.005_b0375","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1021\/bc2001984","article-title":"Simple, direct conjugation of bacterial O-SP-core antigens to proteins: development of cholera conjugate vaccines","volume":"22","author":"Xu","year":"2011","journal-title":"Bioconjug Chem"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21013128?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21013128?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T08:17:43Z","timestamp":1777537063000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X21013128"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":75,"journal-issue":{"issue":"47","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S0264410X21013128"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.10.005","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Scalable production and immunogenicity of a cholera conjugate vaccine","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.10.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}